Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization

Beom Kyung Kim, Seung Up Kim, Myeong Jin Kim, Kyung Ah Kim, Do Young Kim, Jun Yong Park, Sang Hoon Ahn, Kwang Hyub Han, Chae Yoon Chon

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purposes: To date, most studies about the optimal number of target lesions for enhancement criteria for hepatocellular carcinoma (HCC) have focused on cross-sectional analyses of concordance. We investigated the optimal number of target lesions for European Association for the Study of the Liver (EASL) andmodified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines in predicting overall survival (OS). Experimental Design: We analyzed 254 consecutive treatment-naïve patients with HCC having at least 2 measurable target lesions undergoing transarterial chemoembolization. Kappa values for intermethod agreement of treatment responses were calculated for comparisons between use of maximum of 1, 2, 3, 4, or 5 targets versus use of all target lesions. Prognostic values of radiologic assessments according to number of target lesions for predicting OS were expressed as C-index. Results: By EASL and mRECIST guidelines, κ values between responses assessing the longest 2, 3, 4, or 5 targets and assessing all targets were 0.924, 0.977, 1.000, or 1.000 and 0.907, 0.959, 1.000, or 1.000, respectively, whereas those between responses assessing only one target and assessing all target lesions were 0.723 and 0.666, respectively. C-index when measuring the longest 1, 2, 3, 4, 5, and all targets was similar, ranging from 0.739 to 0.749 for EASL criteria and from 0.750 to 0.759 for mRECIST. From Cox regression analyses, radiologic response from each calculation method showed independently significant effects on OS for both guidelines, regardless of number of target lesions. Conclusions: Prognostic values for predicting OS were similar regardless of number of target lesions. Assessing the 2 largest targets rather than only 1 index lesion could be recommended considering high concordances from cross-sectional analyses.

Original languageEnglish
Pages (from-to)1503-1511
Number of pages9
JournalClinical Cancer Research
Volume19
Issue number6
DOIs
Publication statusPublished - 2013 Mar 15

Fingerprint

Hepatocellular Carcinoma
Survival
Liver
Guidelines
Cross-Sectional Studies
Research Design
Regression Analysis
Response Evaluation Criteria in Solid Tumors
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{096e90097a5c4b76a261f59b36da984d,
title = "Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization",
abstract = "Purposes: To date, most studies about the optimal number of target lesions for enhancement criteria for hepatocellular carcinoma (HCC) have focused on cross-sectional analyses of concordance. We investigated the optimal number of target lesions for European Association for the Study of the Liver (EASL) andmodified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines in predicting overall survival (OS). Experimental Design: We analyzed 254 consecutive treatment-na{\"i}ve patients with HCC having at least 2 measurable target lesions undergoing transarterial chemoembolization. Kappa values for intermethod agreement of treatment responses were calculated for comparisons between use of maximum of 1, 2, 3, 4, or 5 targets versus use of all target lesions. Prognostic values of radiologic assessments according to number of target lesions for predicting OS were expressed as C-index. Results: By EASL and mRECIST guidelines, κ values between responses assessing the longest 2, 3, 4, or 5 targets and assessing all targets were 0.924, 0.977, 1.000, or 1.000 and 0.907, 0.959, 1.000, or 1.000, respectively, whereas those between responses assessing only one target and assessing all target lesions were 0.723 and 0.666, respectively. C-index when measuring the longest 1, 2, 3, 4, 5, and all targets was similar, ranging from 0.739 to 0.749 for EASL criteria and from 0.750 to 0.759 for mRECIST. From Cox regression analyses, radiologic response from each calculation method showed independently significant effects on OS for both guidelines, regardless of number of target lesions. Conclusions: Prognostic values for predicting OS were similar regardless of number of target lesions. Assessing the 2 largest targets rather than only 1 index lesion could be recommended considering high concordances from cross-sectional analyses.",
author = "Kim, {Beom Kyung} and Kim, {Seung Up} and Kim, {Myeong Jin} and Kim, {Kyung Ah} and Kim, {Do Young} and Park, {Jun Yong} and Ahn, {Sang Hoon} and Han, {Kwang Hyub} and Chon, {Chae Yoon}",
year = "2013",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-12-2721",
language = "English",
volume = "19",
pages = "1503--1511",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. / Kim, Beom Kyung; Kim, Seung Up; Kim, Myeong Jin; Kim, Kyung Ah; Kim, Do Young; Park, Jun Yong; Ahn, Sang Hoon; Han, Kwang Hyub; Chon, Chae Yoon.

In: Clinical Cancer Research, Vol. 19, No. 6, 15.03.2013, p. 1503-1511.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization

AU - Kim, Beom Kyung

AU - Kim, Seung Up

AU - Kim, Myeong Jin

AU - Kim, Kyung Ah

AU - Kim, Do Young

AU - Park, Jun Yong

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

AU - Chon, Chae Yoon

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Purposes: To date, most studies about the optimal number of target lesions for enhancement criteria for hepatocellular carcinoma (HCC) have focused on cross-sectional analyses of concordance. We investigated the optimal number of target lesions for European Association for the Study of the Liver (EASL) andmodified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines in predicting overall survival (OS). Experimental Design: We analyzed 254 consecutive treatment-naïve patients with HCC having at least 2 measurable target lesions undergoing transarterial chemoembolization. Kappa values for intermethod agreement of treatment responses were calculated for comparisons between use of maximum of 1, 2, 3, 4, or 5 targets versus use of all target lesions. Prognostic values of radiologic assessments according to number of target lesions for predicting OS were expressed as C-index. Results: By EASL and mRECIST guidelines, κ values between responses assessing the longest 2, 3, 4, or 5 targets and assessing all targets were 0.924, 0.977, 1.000, or 1.000 and 0.907, 0.959, 1.000, or 1.000, respectively, whereas those between responses assessing only one target and assessing all target lesions were 0.723 and 0.666, respectively. C-index when measuring the longest 1, 2, 3, 4, 5, and all targets was similar, ranging from 0.739 to 0.749 for EASL criteria and from 0.750 to 0.759 for mRECIST. From Cox regression analyses, radiologic response from each calculation method showed independently significant effects on OS for both guidelines, regardless of number of target lesions. Conclusions: Prognostic values for predicting OS were similar regardless of number of target lesions. Assessing the 2 largest targets rather than only 1 index lesion could be recommended considering high concordances from cross-sectional analyses.

AB - Purposes: To date, most studies about the optimal number of target lesions for enhancement criteria for hepatocellular carcinoma (HCC) have focused on cross-sectional analyses of concordance. We investigated the optimal number of target lesions for European Association for the Study of the Liver (EASL) andmodified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines in predicting overall survival (OS). Experimental Design: We analyzed 254 consecutive treatment-naïve patients with HCC having at least 2 measurable target lesions undergoing transarterial chemoembolization. Kappa values for intermethod agreement of treatment responses were calculated for comparisons between use of maximum of 1, 2, 3, 4, or 5 targets versus use of all target lesions. Prognostic values of radiologic assessments according to number of target lesions for predicting OS were expressed as C-index. Results: By EASL and mRECIST guidelines, κ values between responses assessing the longest 2, 3, 4, or 5 targets and assessing all targets were 0.924, 0.977, 1.000, or 1.000 and 0.907, 0.959, 1.000, or 1.000, respectively, whereas those between responses assessing only one target and assessing all target lesions were 0.723 and 0.666, respectively. C-index when measuring the longest 1, 2, 3, 4, 5, and all targets was similar, ranging from 0.739 to 0.749 for EASL criteria and from 0.750 to 0.759 for mRECIST. From Cox regression analyses, radiologic response from each calculation method showed independently significant effects on OS for both guidelines, regardless of number of target lesions. Conclusions: Prognostic values for predicting OS were similar regardless of number of target lesions. Assessing the 2 largest targets rather than only 1 index lesion could be recommended considering high concordances from cross-sectional analyses.

UR - http://www.scopus.com/inward/record.url?scp=84875203282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875203282&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-2721

DO - 10.1158/1078-0432.CCR-12-2721

M3 - Article

C2 - 23225115

AN - SCOPUS:84875203282

VL - 19

SP - 1503

EP - 1511

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -